NLRP3 autophagy-based degrader outlasts its parent inhibitor in colitis
- Starting from an NLRP3 inhibitor known to engage both LC3 and NLRP3, the authors mapped the groups needed for NLRP3 binding and built bivalent autophagy-targeting degraders from it.
- One lead degrader, M3, emerged as the strongest NLRP3 degrader in the series.
- In a colitis model, M3 gave more lasting anti-inflammatory benefit than its inhibitor precursor, supporting degradation over inhibition for this disease.
💡 Points Based on the abstract
Degradation beating inhibition on durability is the expected payoff of removing the protein rather than occupying it. Starting from a dual LC3/NLRP3 binder is a smart shortcut, but I'd worry the LC3 handle is carried by the same pharmacophore. I'd want a clean separation of NLRP3 binding from LC3 binding and the exposure data.